Skip to navigation Skip to main content Skip to footer

Approved Research

Impact of pharmacogenomics (PGx) on pharmacotherapy outcomes in a population with chronic disease

Principal Investigator: Miss Ling Ye
Approved Research ID: 89034
Approval date: August 9th 2022
Central South University

Lay summary

Objectives: Exploring the impact of pharmacogenomics (PGx) on drug therapy outcomes in the chronic disease population

   Scientific rationale: Genetic traits are one of the major contributors to individual differences in drug responsiveness. The effects of PGx on drug absorption, distribution, metabolism, excretion, and adverse effects are well studied, and many organizations have published recommendations for PGx to guide clinical usage of drugs. However, there is still a paucity of research on the impact of PGx on treatment outcomes.

   Project duration: 36 months

   Public health impact: This study will clarify whether there is an effect of PGx on the outcome of medication for chronic diseases, which will support the application of PGx in the clinic and promote precision treatments in chronic disease population.

© UK Biobank Limited 2024 | Registered in England and Wales with company number 4978912.
Registered as a charity in England and Wales (number 1101332) and in Scotland (number SC039230).
Registered office Units 1-2 Spectrum Way, Stockport, Cheshire, SK3 0SA.